Needham & Company initiates coverage on BioCryst Pharma (NASDAQ: BCRX) with a Buy rating and $14 price target, saying BCX4161 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE